Abstract
The discovery of a novel series of therapeutic agents that has been designed and optimized for treating chronic obstructive pulmonary disease is reported. The pharmacological strategy was based on the identification of compounds that inhibit a defined subset of kinase enzymes modulating inflammatory processes that would be effective against steroid refractory disease and exhibit a sustained duration of action after inhaled delivery.
MeSH terms
-
Animals
-
Asthma / drug therapy*
-
Asthma / metabolism
-
Dose-Response Relationship, Drug
-
Drug Discovery*
-
Drug Resistance / drug effects
-
Humans
-
Male
-
Mice
-
Mice, Inbred Strains
-
Molecular Structure
-
Protein Kinase Inhibitors / chemical synthesis
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Protein Kinases / metabolism*
-
Pulmonary Disease, Chronic Obstructive / drug therapy*
-
Pulmonary Disease, Chronic Obstructive / metabolism
-
Steroids / pharmacology
-
Structure-Activity Relationship
-
U937 Cells
Substances
-
Protein Kinase Inhibitors
-
Steroids
-
Protein Kinases